Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of subcutaneous anifrolumab in systemic sclerosis
MOH_2023-08-17_012887Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing Anifrolumab with Placebo (2 arms). Started Jul 2023; status: active, not recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on MOH_2023-08-17_012887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-17_012887.